Compounds > r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid
Page last updated: 2024-09-03

r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Immunoglobulin Light-chain Amyloidosis

r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid has been researched along with Immunoglobulin Light-chain Amyloidosis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barton, SV; Berges, AC; Cookson, LM; Fontana, M; Gillmore, JD; Hawkins, PN; Lane, T; Moon, JC; Pepys, MB; Pinzani, M; Richards, DB; Ritter, JM1

Trials

1 trial(s) available for r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Immunoglobulin Light-chain Amyloidosis

ArticleYear
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    The New England journal of medicine, 2015, Sep-17, Volume: 373, Issue:12

    Topics: Adult; Aged; Amyloidosis; Antibodies, Monoclonal; Carboxylic Acids; Dose-Response Relationship, Drug; Humans; Immunoglobulin G; Immunoglobulin Light-chain Amyloidosis; Infusions, Intravenous; Liver; Middle Aged; Pyrrolidines; Radionuclide Imaging; Serum Amyloid P-Component

2015